Clinical Trials Logo

Clinical Trial Summary

Hypothesis: Girls and women exposed to chemotherapy and/or radiation therapy experience endocrine changes more similar to women in their late reproductive years than to same-age peers. These changes will be more dramatic in women who receive high dose therapy compared to women who receive low dose therapy. At annual visits over 3-5 years, a combination of physical exam, medical history, menstrual diary keeping, pelvic ultrasound and blood hormones tests will be used to measure "ovarian reserve" , that is the number and quality of the eggs that remain in the ovaries. The study will also try to learn if those who received higher doses of certain chemotherapies are more likely to have changes in these tests sooner than those women who received smaller doses of these same drugs. Additionally a DNA (deoxyribonucleic acid) sample will be collected to look for gene variations that may predict susceptibility to ovarian damage from cancer treatments. Information learned from this study may help researchers to develop guidelines to identify problems with a female cancer survivor's ovaries before irregular menses or other symptoms of ovarian failure occur.


Clinical Trial Description

Up to 400 females will participate in this study in one of three cohorts: - 150 females ages 11-35, with history of exposure to alkylating agent chemotherapy and/or radiation therapy - 150 Unexposed peers, ages 11-35, never exposed to chemotherapy or radiation therapy - 100 Unexposed females, ages 40-50 never exposed to chemotherapy or radiation therapy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01143844
Study type Observational
Source University of Pennsylvania
Contact
Status Completed
Phase
Start date March 2006
Completion date March 30, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05529940 - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Phase 3
Recruiting NCT02306837 - Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies Phase 2
Completed NCT02771470 - Intestinal Microflora in Lung Cancer After Chemotherapy Phase 1
Completed NCT02454673 - Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer N/A
Completed NCT02454647 - Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients N/A
Completed NCT01432223 - Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab Phase 2
Completed NCT02767388 - Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Recruiting NCT02555592 - Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level N/A
Suspended NCT02121405 - Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM Phase 3
Recruiting NCT02226380 - FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer Phase 2
Completed NCT03840824 - Blood Spot Self-administered Test and Assay
Completed NCT00911352 - Cryotherapy Intervention for Docetaxel-induced Nail Toxicities Phase 2/Phase 3
Active, not recruiting NCT01490060 - Fosaprepitant in Patients Receiving Ifosfamide-based Regimen N/A
Completed NCT02395341 - The Longitudinal Ovarian Reserve Study N/A
Recruiting NCT05268991 - Aging and Frailty Study
Recruiting NCT03885388 - Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6 Phase 2/Phase 3
Completed NCT02375776 - Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention N/A
Enrolling by invitation NCT02074241 - Molecular Markers of Chemosensitivity for Bladder Cancer N/A
Recruiting NCT02169388 - Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy Phase 1
Completed NCT03402295 - Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation Phase 3